Key points
- Point72 (Steven Cohen) disclosed a new 5.3% stake in Evommune (EVMN) in a Schedule 13G filed July 16, 2026.
- The stock had already tanked about 40% on a failed drug trial before Point72's stake even shows up. They bought in anyway.
- EVMN closed at $12.45 the day the stake crossed 5%. It's down to $11.70 since, about 6% lower.
- The filing doesn't disclose what Point72 paid, so whether the fund is up or down on it right now is genuinely unknown.
Point72, the fund run by Steven Cohen, disclosed a new stake in Evommune (EVMN) today: 5.3% of the company, filed on a Schedule 13G. The stake size isn't really the interesting part. The timing is.
What the filing actually says
Three names are on this filing, and they're really one chain of control. Point72 Asset Management is the entity that manages the money. Point72 Capital Advisors is its general partner. Cohen sits above both. That's why the same share count shows up three times on the cover pages, it's the same stake, reported once for each link in the chain.
This is one we caught through our own tracker on Point72, part of the 40 funds we watch for fresh SEC filings as they land.
The position works out to 5.3% of Evommune's stock. It's filed as a 13G, not a 13D, which matters here. A 13D is for someone trying to influence or control a company. A 13G is the passive version, and this one comes with the standard certification that the shares weren't bought to change who runs Evommune. Point72 also isn't holding any of it with sole voting or dispositive power, all of it's shared, which is normal for a fund structure like this one and not a sign of anything unusual.
The timing that changes the story
Here's the part that made me want to write about it. On June 29, Evommune's lead drug, EVO756, failed its Phase 2b trial for chronic hives. It missed the primary endpoint at every dose tested. The stock fell about 40% that day, from $25.18 down to a low near $15, on volume more than ten times normal. A handful of analysts downgraded the stock the same day.
Point72's filing lists July 15 as the date its stake crossed 5%. That's more than two weeks after the crash, not before it. A 13G doesn't say exactly when Point72 started buying or how it built the position over those two weeks, but the date it's required to disclose is the date it passed the threshold, and that date sits well into the aftermath, not the disaster itself. The stock had already tanked. Point72 bought anyway.
Is Point72 up or down on it?
Here's where I have to be honest about what this filing does and doesn't tell you. It doesn't say what Point72 paid. Since the crash, EVMN has mostly traded in a band between about $11.50 and $14. Wherever Point72's average cost landed inside that range, the stock has been drifting toward the bottom of it, not the top. It closed at $12.45 on July 15, the day the stake crossed 5%, and it's already down to $11.70 as of today. That doesn't prove a loss. It does mean the odds aren't running in Point72's favor at the moment.
None of this is unusual for how a multi-strategy fund like Point72 operates. Buying into a name right after a binary event has already broken it, rather than trying to predict the event, is its own kind of bet: that the selling is overdone, or that something else in the pipeline still has value the market isn't pricing. Whether that's the read here isn't something a 13G can tell you either way.
Point72 has shown up in this kind of situation before, disclosing a stake in Freenome's SPAC merger days before that deal's vote got delayed. Different company, same pattern worth watching: a big name moving into a stock right around when something else is already in motion.
Point72 runs more than 200 investing teams, so a disclosed stake is one team's position rather than a house view. See our explainer on what a pod shop is.
This is general market commentary and not investment advice. Always do your own research and consider speaking with a licensed financial professional before making any investment decision.
